NCT07077902 - A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions

Hidradenitis Suppurativa

Interventions

DRUG

Topical roflumilast 0.3% foam

Topical roflumilast is a potent phosphodiesterase 4 (PDE4) inhibitor approved for the treatment of psoriasis, seborrheic dermatitis and atopic dermatitis

Trial Locations (4)

70001

Lakeside Hospital, New Orleans

70112

LCMC Multi-speciality Clinic, New Orleans

University Medical Center, New Orleans

70433

Lakeview Hospital, Covington